# Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

> **NCT00628420** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ACP-104
- **DRUG:** ACP-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00628420
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-11
- **Final completion:** 2007-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2011-06-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628420, "Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00628420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*